Literature DB >> 12403310

Pimecrolimus: a new treatment for seborrheic dermatitis.

Charles E Crutchfield1.   

Abstract

Seborrheic dermatitis is a chronic recurrent inflammatory skin condition that mainly affects areas containing sebaceous glands. I present a case of a novel effective topical nonsteroidal treatment (pimecrolimus 1.0% cream) for facial seborrheic dermatitis. Pimecrolimus is a member of a new class of nonsteroidal agents- macrolactam immunomodulators.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12403310

Source DB:  PubMed          Journal:  Cutis        ISSN： 0011-4162


  3 in total

Review 1.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials.

Authors:  Odeh Alsmeirat; Som Lakhani; Musab Egaimi; Osama Idris; Mohamed Elkhalifa
Journal:  Cureus       Date:  2022-08-02

3.  Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients.

Authors:  Byung-Soo Kim; Su-Han Kim; Moon-Bum Kim; Chang-Keun Oh; Ho-Sun Jang; Kyung-Sool Kwon
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.